We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Using Drop-Based Microfluidics to Treat Flu

News   Jan 25, 2017 | Original story from Montana State University

 
Using Drop-Based Microfluidics to Treat Flu

Credit: Adrian Sanchez-Gonzalez

 
 
Advertisement
 

RELATED ARTICLES

Oxford's COVID-19 Vaccine Has 70% Efficacy Rate

News

There are now over 170 teams of researchers working to develop a vaccine for protection against COVID-19. Over the last few weeks, a number of groups shared interim analysis data on candidates that have reached Phase III clinical testing. The latest addition is the University of Oxford – in collaboration with the pharmaceutical company AstraZeneca – who today announce an efficacy of 70.4% for the candidate, ChAdOx1 nCoV-2019.

READ MORE

COVID-19 Vaccine Distribution Must Include Prison Populations, Study Says

News

Preventing serious complications from COVID-19 in potentially vulnerable populations in high risk environments, such as prisons, and preventing spread to surrounding communities needs a coordinated evidence-based approach to managing outbreaks of COVID-19 in prison settings.

READ MORE

Engineered Immune Cells Elicit Broad Response to HIV in Mice

News

Scientists at Scripps Research moved closer to attaining the holy grail of HIV research with a new vaccine approach that would rely on genetically engineered immune cells from the patient’s body.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE